Background and Aims: Crohn's disease-related complications account for a substantial proportion of inflammatory bowel disease-associated health care expenditure. Identifying patients at risk for complications may allow for targeted use of early therapeutic interventions to offset this natural course. We aimed to develop risk prediction models for Crohn's disease-related surgery and complications. Methods: Using data from the Randomised Evaluation of an Algorithm for Crohn's Disease clusterrandomised clinical Trial [REACT], which involved 1898 patients from 40 community practices, separate prediction models were derived and internally validated for predicting Crohn's diseaserelated surgery and disease-related complications [defined as the first disease-related surgery, hospitalisation, or complication within 24 months]. Model performance was assessed in terms of discrimination and calibration, decision curves, and net benefit analyses. Results: There were 130 [6.8%] disease-related surgeries and 504 [26.6%] complications during the 24-month follow-up period. Selected baseline predictors of surgery included age, gender, disease location, Harvey-Bradshaw Index [HBI] score, stool frequency, antimetabolite or 5-aminosalicylate use, and the presence of a fistula, abscess, or abdominal mass. Selected predictors of complications included those same factors for surgery, plus corticosteroid or anti-tumour necrosis factor use, but excluded 5-aminosalicylate use. Discrimination ability, as measured by validated c-statistics, was 0.70 and 0.62 for the surgery and complication models, respectively. Score charts and nomograms were developed to facilitate future risk score calculation. Conclusions: Separate risk prediction models for Crohn's disease-related surgery and complications were developed using clinical trial data involving community gastroenterology practices. These models could be used to guide Crohn's disease management. External validation is warranted.
Introduction
Crohn's disease [CD] is an idiopathic disorder of the gastrointestinal tract, characterised by chronic, segmental inflammation, which typically has a relapsing and remitting course. Despite the use of immunosuppressive maintenance therapies, subclinical transmural inflammation persists in many patients, 1 which predisposes them to such complications as strictures and fistulas. 2 Recent studies estimate the long-term risk of surgery to be approximately 60-80%, [2] [3] [4] [5] with the greatest risk in the first few years following diagnosis.
In the past two decades, the advent of biologic therapies and refinement of treatment paradigms have revolutionised the medical management of CD. Specific advances include the introduction of tumour necrosis factor [TNF] antagonists [6] [7] [8] [9] [10] [11] [12] [13] and integrin inhibitors, [14] [15] [16] [17] [18] the use of combination therapy, [19] [20] [21] [22] therapeutic drug monitoring, 23, 24 and earlier initiation of effective therapies in high-risk patients. 12, [19] [20] [21] [25] [26] [27] [28] [29] However, one of the greatest challenges in implementing these strategies is determining which patients are most at risk for complicated disease and thus candidates for more intensive monitoring and treatment. This decision is usually based on clinical judgement and heavily weighted by the patient's disease activity as assessed by symptoms. This approach is practical, but it does not routinely incorporate prognostic factors that drive disease-related complications. Accordingly, identification of patients at highest risk of complications and disease progression, who have the greatest chance of benefiting from early initiation of effective therapy, is an aspirational goal.
In this regard, the approach to therapy in CD has changed dramatically. Formerly, 'step-care', in which drugs are used sequentially to attain symptomatic remission, was the preferred paradigm. Whereas this approach is attractive because it avoids over-treating low-risk patients, step-care delays initiation of effective therapy in patients most at risk for adverse outcomes. Recently, attention has turned to early introduction of combination immunosuppression therapy in high-risk patients, to promote mucosal healing and minimise exposure to corticosteroids. 19, 20 This 'top-down' approach requires accurate identification of high-risk patients, to minimise over-treatment in lower-risk patients, with the associated risk of treatment-related adverse events and costs. Conversely, misclassification of high-risk patients delays administration of effective therapies and potentially results in increased risk of complications. Therefore, the ability to accurately risk-stratify patients has garnered considerable interest. 30, 31 Retrospective analyses of single-centre and population-based cohorts have identified several prognostic factors in CD, including younger age at diagnosis, ileal disease location, perianal disease, stricturing or penetrating phenotype, current smoking, treatment with corticosteroids at diagnosis or corticosteroid dependence, and extensive disease involvement. 1, [3] [4] [5] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Existing clinical prediction models have several limitations. Notably, these models were developed from single centres, referral centres, retrospective samples, small development samples, or cohorts assembled before the widespread use of TNF antagonists, and they often predict excessively long-term risk estimates of outcomes [5-10 years] . 32, 33, [41] [42] [43] [44] However, to fully utilise this information, prediction models must be established.
Data arising from randomised trials offer a unique ability in developing clinical prediction models, because of their scope, size, multicentre participation and prospective follow-up, thus overcoming some of the aforementioned design limitations. We developed and internally validated clinical prediction models for CD using data from a large cluster randomised trial conducted throughout community practices, comparing two treatment algorithms for CD. 21 Our specific aim was to develop separate models for predicting risks of two binary endpoints within 24 months of follow up: [1] occurrence of CD-related surgery; and [2] occurrence of a composite of CD-related surgery, complications or hospitalisation [this composite outcome is henceforth referred to as disease-related complications].
Methods

Data source
The study population was participants from the Randomised Evaluation of an Algorithm for Crohn's Disease [REACT] trial [NCT01030809]. 21 Briefly, REACT was a large, cluster-randomised, controlled trial of two distinct algorithms for the management of CD. Forty Canadian and Belgian community-based gastroenterology clinics were randomised, in a 1:1 ratio, to either early combined immunosuppression or step-care. In each clinic, consecutive adult patients with CD were enrolled, regardless of disease activity or concurrent therapy, and followed up to 24 months. The dataset was used to develop separate models to predict the risk over 24 months of having CD-related surgery and disease-related complications. 45 
Clinical outcomes and definitions
Binary outcomes were defined within 2 years of follow up. The first was the occurrence of CD-related surgery. The second was a CD-related complication. Surgery was considered separately since it is a readily measured event of clinical importance. All events in the REACT trial used in this study were evaluated by an adjudication committee who were blinded to treatment assignment. 
Selection of predictors
Candidate prognostic factors were selected from the demographic and disease-related variables, using standardised clinical definitions, collected at baseline and before treatment allocation. A search of the literature identified potential prognostic factors of interest that were augmented by clinical judgement. These variables were age at enrolment, age at diagnosis, gender, smoking status, disease location, perianal disease, previous surgical resection for CD, use of each medication at baseline [including 5-aminosalicylates, corticosteroids, immunosuppressives, and TNF antagonists], abdominal pain, abdominal mass, extra-intestinal manifestations, strictures, fistulas, and stool frequency. No laboratory parameters, biomarkers, or cross-sectional imaging items were included. Since the purpose of these models is to predict risks using baseline factors before treatment allocation, treatment assignment was not considered as a predictor in the models. Moreover, coefficients for treatment effect were relatively small compared with other prognostic factors.
Missing data
No participants had missing outcome data. However, 4.24% [n = 84] of patients had at least one missing variable at baseline, of which it was most common to be missing components of the HBI score. No patterns were observed in the missing values. Only participants with complete baseline data were used for model development.
Model development
Exploratory univariate data analysis was first conducted to assess adequate event frequency between each outcome and the candidate prognostic factors. Univariable associations between candidate predictors and the outcomes were assessed graphically and using logistic regression. Each model was then constructed using multivariable logistic regression analysis. Predictors with univariate associations p < 0.20 entered the multivariable model. From this full model, unnecessary variables were removed based on a difference in Akaike information criteria [AIC; < 2.0]. In terms of the relative performance of models as estimated from bootstrap replicates, the removal of these variables had a negligible impact on discrimination, the Brier score [< 1% difference in mean difference], and calibration. Although the data arose from a cluster-randomised trial, regression coefficient estimates are not much affected when the degree of clustering is low as in this trial [intraclass correlation coefficient < 0.02]. 46 Since the focus in prediction studies is on the absolute risk estimate from the combined predictor effects, these analyses were conducted at the patient level without accounting for clustering.
Predictive performance and model validation
The model development and validation process adhered to recommended guidelines. 47, 48 Model performance was characterised by the discrimination ability and calibration: the discrimination ability of a model to distinguish between patients with the outcome and patients without the outcome. In the present context, discrimination is measured using the c-statistic, which is identical to the area under the receiver operating characteristic curve for binary outcomes. 49 A value of 0.50 for the c-statistic represents the prognostic ability of a coin flip and will therefore correctly differentiate 50% of cases. There are no universal guidelines for describing the quality of discrimination ability, but generally discrimination values below 60% are unacceptable, 60% to 70% may be acceptable and values from 70% to > 90% range from good to excellent. The interpretation of these values is context-dependent. Calibration refers to the agreement between predicted and observed risks. 47 This can be assessed by plotting the predicted risks and the observed percentages of patients who had the outcome.
Since model development tends to over-fit the data, commonly referred to as optimism, it is desirable to reduce optimism using internal validation and/or external validation. 50 Internal validation of the models was conducted using the bootstrap method with 500 replicates. 51 Performance characteristics were calculated for the original [index] and validated models following correction for optimism. Additional details regarding statistical methodology and performance measures are provided in the Supplementary Appendix, available at ECCO-JCC online.
Sample size
Formal sample size calculation was not conducted. Of the 1982 participants in the REACT trial, 504 had disease-related complications and 130 had surgeries over 2 years of follow-up. According to the guideline of 10 events per variable, 52 this dataset is large enough to construct prediction models with at least ten predictors. 
General statistical methods
Results
Patient characteristics and clinical outcomes
Baseline characteristics are outlined in Table 1 . A total of 1097 [57.79%] patients were female. Median disease duration was 148.8 months, the mean HBI was 4.1, and almost one-third of patients were taking biologics at baseline. Over the 24-month follow-up period, 6.84% [n = 130] of participants underwent CD-related surgery, and 26.55% [n = 504] of participants experienced a CD-related complication. Univariate associations for each outcome are shown in Table 2 .
Model performance and validation
A separate logistic regression model was estimated for each outcome. Table 3 shows the estimates of regression coefficients for the Table 4 . A risk score may alternatively be calculated using score charts and converted to a risk estimate [ Tables  5 and 6 ] or computed by the provided nomograms [ Figure 1A and B].
xp( ) . An example risk calculation is demonstrated in
For prediction of CD-related surgery, the score ranges from 0 to 233 [ Table 5 ]. A score of 61, 119, or 171 respectively predict a 5%, 20%, or 50% chance of experiencing a disease-related surgery within 24 months of follow-up. For prediction of CD-related complications, the score ranges from 0 to 314 [ Table 6 ]. A score of 88, 177, or 266 respectively predict a 25%, 50%, or 75% chance of experiencing a disease-related complication within 24 months of follow-up.
Discussion
We developed two clinical prediction models, one for predicting individual risk of experiencing CD-related surgery, and the other for Table 4 . Computing the predicted risk score.
As an example, suppose a 50-year old male patient presents to the clinic with disease confined to the small bowel. His total HBI score is 3 with a stool frequency of two per day, he is currently taking 5-ASA, and does not have a fistula, stricture, or definite abdominal mass. predicting CD-related complications within 24 months, using data from one of the largest clinical trials conducted in CD to date. These models have been developed using patients from the REACT trial, and are thus intended for use in a broad cross-section of patients found in community gastroenterology clinics and not solely with regard to a specific disease duration or severity. Although both models demonstrated high specificity and negative predictive values, the surgery model had relatively greater predictive ability, likely because surgery is an easily defined and more objective clinical outcome, compared with disease-related complications. Additionally, the development of a score chart using basic clinical variables which are readily calculable facilitates implementation of this score in the outpatient clinic setting, potentially allowing for enhanced decision making between patients and physicians. If validated in an external dataset, the use of this model may help identify patients at higher risk of disease-related complications and especially surgery, who may benefit most from more intensive treatment, combination therapy, and/or closer monitoring for symptoms that require planned surgery [eg. obstructive symptoms in the setting of fibrostenotic disease]. Additionally, all identified baseline predictors in our models were prospectively defined and measured. We believe this is a distinct advantage to retrospective cohort studies in which a greater potential exists for bias during the data acquisition process.
Existing prediction models for CD-related outcomes [summarised in Supplementary Table 5 , available at ECCO-JCC online] have been limited by selection or referral centre bias, small sample size, evolving drug treatments and management strategies, long-term time horizons, or broadly inclusive outcome definitions. Furthermore, the time frame in which these models were produced must be considered. Since the greatest risk of complications occurs within the first few years after diagnosis, long-term risk prediction models eventually become confounded or outdated with evolving therapies and treatment strategies. For example, while some models were developed in the pre-biologic era, others define the need for thiopurines as advanced disease; but currently thiopurine monotherapy represents a treatment strategy generally reserved for less severe disease rather than severe disease. 55, 56 Nevertheless, it is notable that many of the items we identified as independent predictors have previously been shown to have prognostic value in population-based cohorts with longer-term follow up, 1, 4, [57] [58] [59] [60] supporting the validity of our results. Prediction of CD-related complications is limited by the use of nonstandard or broadly inclusive outcome definitions [Supplementary Table 5 ], thus preventing meaningful comparisons with our model. This may also explain the lower performance of the model for prediction of CD-related complications.
In the present study, the surgery model has shown promise to accurately predict an adverse outcome which may be useful to guide management strategies and patient care. Such a model could also reasonably be used for risk stratification of patients in clinical studies.
A major strength of the current study is use of data from a large randomised controlled trial [RCT] conducted across community centres, meaning that the endpoints were well defined, complete to 24 months of follow-up, and adjudicated by an independent panel. The pragmatic nature of the trial design meant that consecutive patients were enrolled, regardless of disease activity, duration, phenotype, or treatment, and an algorithm of care applied which is broadly representative of the patient population seen in clinical practice. Thus, we believe these models may be more generalisable to the routine clinical care of adult patients with CD, and can be applied within the community clinic, regardless of disease duration, in keeping with the design of the trial from which the model and data were derived.
It is interesting to point out that smoking is commonly regarded as a poor prognostic factor for Crohn's disease and especially for postoperative recurrence. In the present study, we found that smoking had limited predictive ability for CD-related complications. Another important consideration with smoking is that there is a Table 6 . Score chart for risk of CD-related complications.
CD, Crohn's disease; HBI, Harvey-Bradshaw Index; TNF, tumour necrosis factor. degree of subjective reporting, which can lead to inaccurate categorisation of current/recent/past smoking status as well as confounding with the quantity of smoking. Thus, we did not retain this in the final prediction models, which did not appreciably affect predictive performance.
Limitations of this study should be acknowledged. Perhaps the greatest limitation is that these models were validated in the cohort in which they were developed. Thus, independent validation in an external dataset is required before the widespread adoption of any prediction model can be considered. The results presented here encourage seeking such external validation. Participants in the REACT study had a longer average duration of disease, though approximately 15% and 28% were diagnosed within 2 and 5 years, respectively. However, the operating characteristics of these models in only newly diagnosed patients remain to be determined. Indeed, the REACT design was intended to include a broad cross-section of patients within community clinics, so that we may not be limited to specific subsets of disease or demographic characteristics, and applies more generally to a broader patient population.
The CD-related surgery model performed better than the complication model, which may be related to using a more well-defined and objective outcome definition. Although the models use routinely available and clearly defined clinical data collected by trained gastroenterologists, inter-observer variability may influence the validity of the model. Also, the REACT study did not include biomarkers or serological or genetic factors; therefore these factors could not be incorporated into the current models. These factors may provide additional prognostic value beyond routine clinical data. 41 Related to this issue of validation is discrimination performance. Prediction of CD-related complications is relatively difficult, as reflected in its low discriminative ability. However, the surgery model performs nominally as well as the model by Siegel and colleagues, 43 using completely different modelling approaches and relying solely on readily available clinical variables. Nevertheless, we are cautiously optimistic that the surgery model may prove useful once externally validated. The treatment allocation was not included in our models, which some may view as a limitation. However, this decision was made a priori for two reasons. First, our primary interest was to develop prediction models using only baseline predictive factors that are available in practice. Second, the effect of treatment to predict these outcomes was found to be relatively small as compared with the factors in our prediction models. This is consistent with prediction literature in other areas, such as cardiovascular disease. 61 In summary, we have developed and validated clinical prediction models for CD-related surgery and complications using data from a large randomised clinical trial with good overall performance for predicting the outcome of disease-related surgery within 2 years. We have transformed these models into scoring tools, facilitating their use in the clinic; external validation in independent cohorts with longitudinal follow up is recommended.
Funding
This work was not specifically supported by any funding agency in the public, commercial, or not-for-profit sectors. 
